BioLineRx (BLRX) Capital Expenditures (2013 - 2024)
BioLineRx's (BLRX) quarterly Capital Expenditures came in at $6000.0 in Q4 2024, up 137.5% year-on-year from $2526.3 in Q1 2024, and up 122.22% quarter-over-quarter from -$27000.0 in Q2 2024.
BioLineRx (BLRX) Capital Expenditures (2013 - 2024) Analysis & Trends
BioLineRx's Capital Expenditures history runs 12 years deep, the most recent figure standing at $6000.0 for Q4 2024.
- On a quarterly basis, Capital Expenditures rose 137.5% year-over-year to $6000.0 in Q4 2024; TTM through Dec 2024 was -$53000.0, a 54.31% increase from a year earlier, with the FY2025 full-year figure at -$25000.0, up 52.83% from the prior year.
- Capital Expenditures improved to $6000.0 in Q4 2024 per BLRX's latest filing, from -$27000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $6000.0 in Q4 2024 and bottomed at -$67000.0 in Q2 2023.
- The 5-year median for Capital Expenditures is -$19000.0 (2021), against an average of -$24750.0.
- Across the five-year window, Capital Expenditures plunged 6300.0% in 2021 and soared 137.5% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $1000.0 in 2020, then plunged by 6300.0% to -$62000.0 in 2021, then advanced by 8.06% to -$57000.0 in 2022, then jumped by 71.93% to -$16000.0 in 2023, then surged by 137.5% to $6000.0 in 2024.
- Per Business Quant, the three latest BLRX Capital Expenditures figures stand at $6000.0 (Q4 2024), -$27000.0 (Q2 2024), and -$32000.0 (Q1 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -67,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -57,000.00 |
| Dec 31, 2022 | -57,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Jun 30, 2022 | -44,000.00 |
| Jun 30, 2022 | -44,000.00 |